Rhon-klinikum Ag · XETR:RHK
Rhon-klinikum — Q1 2019 Earnings Presentation
11 slides from Rhon-klinikum's earnings presentation, May 3, 2019
Slide 1: First Quarter 2019 Results
First Quarter 2019 Results 3 May 2019 RHÖN-KLINIKUM AG - First Quarter 2017 Results - as of May 5, 2017 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by RHÖN-KLINIKUM AG (the “Company”) and is for information purposes only. This presentation does not constitute, or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any
Slide 3: Highlights Q1 2019
Highlights Q1 2019 A successful first quarter with solid growth figures despite start-up effects of the new Campus Revenues €324.2m (+4%)/EBITDA €28.7m (+4%) Treated patients 218.924 (+1.1%) New RHÖN-KLINIKUM Campus Bad Neustadt in operation Flagship facility launched at the turn of the ye
Slide 4: Key P&L figures First quarter of 2019
Key P&L figures First quarter of 2019 Performance* Q1 2019 vs. o Successful Q1 sales growth of +4.0% affected by new outcome in € millions Q1 2018 of negotiations on university outpatient centers Revenue 324.2 100.0% 4.0% o Overall sales growth still limited by regulatory interventions of the legisl
Slide 5: Core balance sheet positions as of 31 March 2019
Core balance sheet positions as of 31 March 2019 €1,604m €1,604m 66% €1,064m Non-current assets €1,168m Equity ratio Equity 73% €540m 34% Current assets €128m Non-current liabilities 8% €308m €189m Cash Current liabilities 19% Assets Equity & liabilities Solid balance sheet and Strong equity ratio
Slide 6: AGM 2019 Dividend proposal
AGM 2019 Dividend proposal Management Board and Supervisory Board jointly propose to the AGM to distribute a dividend of €0.29 per share (+32% compared to the previous year) Based on the currently outstanding number of shares in the amount of 66.94 million, the total dividend will amount to €19.4m D
Slide 7: Outlook 2019 Assumptions & key drivers
Outlook 2019 Assumptions & key drivers GUIDANCE Group REVENUES €1.30bn +/- 5% fully 2019 confirmed Group EBITDA €117.5m to €127.5m Assumptions and key levers* +1.8% DRG price effect on group revenues +2.8% DRG volume growth on group revenues after catalogue effect Further growth from additiona
Slide 8: Financial Calendar for FY 2019
Appendix Financial Calendar for FY 2019 22 February 2019 Preliminary results for financial year 2018 Conference call 29 March 2019 Publication of annual financial report 2018 Annual Press Conference 10 April 2019 Capital Markets Day (Campus Bad Neustadt) 3 May 2019 Publication of interim rep
Slide 9: Price Regulation in 2019 at a Glance
Appendix Price Regulation in 2019 at a Glance Average base rate increase in states with RHÖN hospitals Federal Total hospital system budget (weighted by RHÖN case mix) Level Wage sum increase as main reference number for RHÖN effective base rate Benchmark (wage sum) 1 DRG inflation in 2019: +2.65%
Slide 10: Shareholder base
Appendix Shareholder base Shareholder structure as of 31 March 2019, according to the most recent notifications of voting rights at that time 25.2% 24.5%* B. Braun 24.5% Free Float 5.2% 75.5% Landeskrankenhilfe Strategic Investors 5.4% 25.1% Ingeborg Münch Asklepios 14.6% Eugen Münch/HCM SE * Shareh
Slide 11: IR contact information
Appendix IR contact information Contact Julian Schmitt Head of Investor Relations & Treasury tel +49 9771 65 1536 email ir@rhoen-klinikum-ag.com RHÖN-KLINIKUM AG – Appendix 11